- Home
- IONS vs CRUS Comparison
IONS vs CRUS Comparison
Compare IONS & CRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CRUS
- Stock Information
- Founded
- IONS 1989
- CRUS 1984
- Country
- IONS United States
- CRUS United States
- Employees
- IONS N/A
- CRUS N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CRUS Semiconductors
- Sector
- IONS Health Care
- CRUS Technology
- Exchange
- IONS Nasdaq
- CRUS Nasdaq
- Market Cap
- IONS 5.4B
- CRUS 5.2B
- IPO Year
- IONS 1991
- CRUS 1989
- Fundamental
- Price
- IONS $33.51
- CRUS $98.36
- Analyst Decision
- IONS Buy
- CRUS Strong Buy
- Analyst Count
- IONS 18
- CRUS 5
- Target Price
- IONS $57.41
- CRUS $126.40
- AVG Volume (30 Days)
- IONS 1.5M
- CRUS 685.1K
- Earning Date
- IONS 04-30-2025
- CRUS 05-06-2025
- Dividend Yield
- IONS N/A
- CRUS N/A
- EPS Growth
- IONS N/A
- CRUS 22.45
- EPS
- IONS N/A
- CRUS 6.00
- Revenue
- IONS $717,253,000.00
- CRUS $1,896,077,000.00
- Revenue This Year
- IONS $7.14
- CRUS N/A
- Revenue Next Year
- IONS $18.89
- CRUS $8.00
- P/E Ratio
- IONS N/A
- CRUS $16.39
- Revenue Growth
- IONS N/A
- CRUS 5.99
- 52 Week Low
- IONS $23.95
- CRUS $75.83
- 52 Week High
- IONS $52.34
- CRUS $147.46
- Technical
- Relative Strength Index (RSI)
- IONS 56.80
- CRUS 46.13
- Support Level
- IONS $32.00
- CRUS $99.00
- Resistance Level
- IONS $33.65
- CRUS $103.03
- Average True Range (ATR)
- IONS 1.08
- CRUS 2.29
- MACD
- IONS -0.10
- CRUS -0.91
- Stochastic Oscillator
- IONS 55.72
- CRUS 11.51
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About CRUS Cirrus Logic Inc.
Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.